间三氟甲基苯乙酮置于盐酸 Sodium Tetrahydroborate,氯化亚砜,碳酸氢钠,Sodium Hydroxide体系中,用 甲醇,乙醇,水,甲苯 作为反应溶剂,-10.0~30.0 °C,100.0 Kpa 条件下,反应 5.58H,反应生成 盐酸甲状旁腺激素 参考文献: Process For Preparing Cinacalcet[fr] Procede De Preparation De Cinacalcet 标题: Process For Preparing Cinacalcet[fr] Procede De Preparation De Cinacalcet 摘要:一种制备化学式为盐酸盐(I)的n-[(1R)-1-(1-萘基)乙基]-3-[3-(三氟甲基)苯基]丙基胺(即cinacalcet.Hcl)及其中间体化学式为(Ix)的方法.
专利号:US-8614354-B2 优先权日:2008-06-18 标题 :Process for the synthesis of cinacalcet hydrochloride 发明人:FERRARI MASSIMO; GHEZZI MARCELLO; BONALDI MATTEO 权利人:FERRARI MASSIMO; GHEZZI MARCELLO; BONALDI MATTEO; ERREGIERRE SPA 摘要:There is described a process for the preparation of cinacalcet hydrochloride (I) which includes the steps of: a) reacting (R)-(+)-1-(1-naphthyl)ethylamine (II) with 3-[3-(trifluoromethyl)phenyl]propenaldehyde (III) to afford the non isolated intermediate (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenylimino-N-[1-(1-naphthyl)ethylamine (IV); b) reducing the non isolated intermediate (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenylimino-N-[-1-(1-naphthyl)ethylamine (IV) with a sequential addition of:—a solution of sodium borohydride, methanol and a base,—oxalic acid and—a base to obtain (R)—N-[3-[3-(tifluoromethyl)phenyl]-2-propenyl]-1-(1-naphthyl)ethylamine (V) by passing through the precipitation of the oxalate salt of compound (V) after the addition of oxalic acid; c) hydrogenating (R)—N-[3-[3-(trifluoromethyl)phenyl]-2-propenyl]-1-(1-naphthyl)ethylamine (V) thus obtaining (R)—N-(3-(3-(trifluoromethyl)phenyl]propyl]-1-(1-naphthyl)ethylamine cinacalcet base (VI), which is retaken in ethyl acetate; and d) treating the solution of cinacalcet base (VI) in ethyl acetate with hydrochloric acid to afford cinacalcet hydrochloride (I).
专利号:WO-2025099741-A1 优先权日:2023-11-07 标题:Process for the preparation of nitrosamine free cinacalcet and salts thereof 发明人:BIRARI DILIP RAMDAS; SHINDE GORAKSHANATH BALASAHEB; TELDHUNE Ashish Pramod 权利人:MEGAFINE PHARMA P LTD; BIRARI DILIP RAMDAS; SHINDE GORAKSHANATH BALASAHEB; TELDHUNE Ashish Pramod 摘要:The present invention relates to a process for preparation of nitrosamine free Cinacalcet (1) and salts thereof. Wherein, Cinacalcet (1) and its salts is substantially free of nitrosamine impurities by using of an antioxidant in the process for synthesis of Cinacalcet (1) and its pharmaceutically acceptable salts.
专利号:US-2010267988-A1 优先权日:2006-06-08 标 题:Processes for preparing intermediate compounds useful for the preparation of cinacalcet 发明人:SZEKERES TIBOR; REPASI JOZSEF; SZABO ANDRAS; MANGION BERNARDINO 权利人:MEDICHEM SA 摘要:The invention relates, in general, to an improved process for preparing compounds (e.g., 3-(3-trifluoromethylphenyl)propanal (Compound III, below)), which are key intermediates for the synthesis of cinacalcet, its salts and/or solvates thereof, as well as the use of such compounds prepared by such process for the preparation of cinacalcet and/or its salts or solvates.
专利号:EP-1990333-A1 优先权日:2007-05-11 标题 :Process for the preparation of cinacalcet hydrochloride 权利人:SANDOZ AG 摘要:The present invention relates to a process for the preparation of cinacalcet hydrochloride which is industrially feasible and commercially viable. The synthesis of cinacalcet hydrochloride is carried out by the condensation of 3-trifluromethylphenyl propionic acid with R-(+)-1-(lnaphthyl)ethylamine.
专利号:WO-2015071831-A1 优先权日:2013-11-18 标 题 :An improved process for minimising the formation of dehalogenated byproducts 发明人:KADAM SHASHIKANT; ARADDY RAJSHEKAR; KONDRAGUNTA VENKATESWARA RAO; HULAVALE YOGESH; SOMISETTI NARENDER RAO; CHENNAMSETTY SUNEEL MANOHAR BABU; HARIHARAN SIVARAMAKRISHNAN 权利人:PIRAMAL ENTPR LTD 摘要:The present invention provides an improved process for preparation of organic compounds represented by Formula-Z; wherein effectively minimising the formation of dehalogenated by-products is achieved. In the process, the reduction is carried out using suitable reducing agent; more preferably Lithium Aluminium Hydride (LAH) in a solvent system, wherein at least one of the solvent is selected from halogenated solvents, which acts as co-solvent. The process of the present invention is useful for minimising of the formation of dehalogenated by-products during synthesis of various active pharmaceutical ingredients such as Paroxetine Hydrochloride, Cinacalcet, Eletriptan and Asenapine.
专利号:US-7361789-B1 优先权日:2004-07-28 标 题 :Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis 发明人:YAN QI; ORIHUELA CARLOS; SHEN BO; CHEN YING; WANG XIN; NG JOHN; JI RUIZHI; ZHOU PENGZU 权利人:AMGEN INC 摘要:The present invention relates to novel dihydronaphthalene compounds, compositions, methods for using the same, and processes for preparing the same. The present invention also relates to novel total synthesis approaches for preparing these compounds. In addition, the present invention relates to methods of producing quantities of isomers of these compounds and separating and purifying them using chiral separation techniques. The present invention also relates to methods of producing quantities of a single isometric compound without the need for chiral separation techniques.
1: Del Prete M, Marotta V, Ramundo V, Marciello F, Di Sarno A, Esposito R, Carratù AC, De Luca Di Roseto C, Di Somma C, Colao A, Faggiano A. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Minerva Endocrinol. 2013 Dec;38(4):389-94. doi: 10.3109/0886022X.2013.832319. Epub 2013 Sep 24. Review. doi: 10.1111/1744-9987.12292. Epub 2015 Apr 7. doi: 10.1517/14656566.2013.777041. Epub 2013 Mar 4. Review. Review. Japanese. doi: 10.1007/s10157-014-1045-3. Epub 2014 Nov 11. 7: Padhi D, Harris R, Sullivan JT. Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet. Clin Drug Investig. 2014 Aug;34(8):537-44. doi: 10.1007/s40261-014-0206-1. doi: 10.1111/1744-9987.12035. Epub 2013 Mar 28. doi: 10.1053/j.ajkd.2011.12.034. Epub 2012 Mar 24. doi: 10.2147/IJNRD.S54731. eCollection 2013. 11: Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9. doi: 10.1007/s12020-014-0381-0. Epub 2014 Aug 15. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.
合成参考文献
参考文献:10.1016/j.bmcl.2018.04.055 摘要:Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, Kuroda M, Hisada Y, Yanagida T, Yoneda H, Tsukumo Y, Tokunaga S, Kawata T, Ohashi R, Fukuda H, Kojima K, Kannami A, Kifuji T, Sato N, Idei A, Iguchi T, Sakairi T, Moritani Y. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism. Bioorganic & Medicinal Chemistry Letters. 2018 Jun;28(11):2055–60. doi: 10.1016/j.bmcl.2018.04.055.